Related Articles
p53 in esophageal adenocarcinoma: A critical reassessment of mutation frequency and identification of 72Arg as the dominant allele
Immunohistological study of cell cycle-related factors, oncogene expression, and cell proliferation in adenocarcinoma developed in Barrett's esophagus
EMX2 is epigenetically silenced and suppresses epithelial‑mesenchymal transition in human esophageal adenocarcinoma
BARRETTS CARCINOMA IN A 25-YEAR-OLD MAN WITH POINT MUTATION OF THE P53 TUMOR SUPPRESSOR GENE
Epithelial mesenchymal transition and cancer stem cells in esophageal adenocarcinoma originating from Barrett's esophagus